Second, it focuses on the risks, precautions and complications of the use of TNF-α inhibitors in these ... the precise mechanisms of action of TNF-blocking agents remain unresolved.

An international research team led by Geneva University Hospital found no increase in cardiovascular events during the first two years of treatment with Janus kinase inhibitors (JAKi) compared to ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as ... or refraining from, any action on the basis of the content on our site.

Explore why INmune Bio, Inc. is a speculative Strong Buy for high-risk investors. Click for the upcoming catalysts that make ...

In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors Circle Pharma, a clinical-stage biopharmaceutical company focused on ...

Second, abatacept offers an alternative mechanism of action, which gives it a strong position as a second-line biologic therapy for patients who do not respond to their first TNF inhibitor.

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

The poster will present new mechanistic insights into the anti-cancer activity of cyclin A/B RxL inhibitors, including their impact on DNA repair pathways and mitotic progression in E2F-high cancers.

The report elaborates on RAGE inhibitors' mechanism of action, emphasizing factors influencing market growth, including clinical trials, product development activities, mergers and acquisitions, ...